Celltrion boasts worldwide tech lead in biosimilars

South Korea has more biosimilar firepower than just consumer electronics convert Samsung. Celltrion, under the leadership of Seo Jung-jin, is a biosimilars "front-runner," says the CEO. Celltrion has "about four to five years" of a technology lead over rivals, he says. "There will be no serious competitor by 2015, in which period the industry's capacity will be short of demand," Seo says. Story